Antibody therapy for rheumatoid arthritis.

High-quality monoclonal antibodies (mAbs) with specificity for relevant disease molecules can now be produced in abundance. Anti-tumour necrosis factor-alpha therapies have set a new standard for symptom control in rheumatoid arthritis, and blockade of tumour necrosis factor has the potential to pro...

Täydet tiedot

Bibliografiset tiedot
Päätekijä: Taylor, P
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: 2003